The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways.
Antimicrob Agents Chemother
; 66(3): e0239521, 2022 03 15.
Article
in English
| MEDLINE | ID: covidwho-1741569
ABSTRACT
Recently, remdesivir and molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses preexisted in COVID-19 patients. Here we report that remdesivir but not molnupiravir induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), two major oncogenic herpesviruses. Remdesivir induced mature virion production from latently infected cells. Mechanistic studies showed that remdesivir induced KSHV and EBV reactivation by regulating several intracellular signaling pathways.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Herpesvirus 8, Human
/
Epstein-Barr Virus Infections
/
COVID-19 Drug Treatment
Limits:
Humans
Language:
English
Journal:
Antimicrob Agents Chemother
Year:
2022
Document Type:
Article
Affiliation country:
Aac.02395-21
Similar
MEDLINE
...
LILACS
LIS